Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders Equity (Deficit)

v3.21.1
Condensed Consolidated Statements of Changes in Stockholders Equity (Deficit) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2019 $ 0 $ 495 $ (8,055) $ (7,560)
Balance (in shares) at Dec. 31, 2019 2,852,485      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock in exchange for in-process research and development $ 0 2,126 0 2,126
Issuance of common stock in exchange for in-process research and development (in shares) 891,422      
Share-based compensation $ 0 61 0 61
Net and comprehensive loss 0 0 (3,088) (3,088)
Balance at Mar. 31, 2020 $ 0 2,682 (11,143) (8,461)
Balance (in shares) at Mar. 31, 2020 3,743,907      
Balance at Dec. 31, 2020 $ 1 19,207 (32,675) (13,467)
Balance (in shares) at Dec. 31, 2020 10,882,495      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Reclassification of Series A warrant liability to equity $ 0 61,793 0 61,793
Share-based compensation $ 0 494 0 494
Share-based compensation (in shares) 40,000      
Exercise of stock options $ 0 10 0 10
Exercise of stock options (in shares) 7,386      
Net and comprehensive loss $ 0 0 (39,014) (39,014)
Balance at Mar. 31, 2021 $ 1 $ 81,504 $ (71,689) $ 9,816
Balance (in shares) at Mar. 31, 2021 10,929,881